Cannara Biotech Inc.
LOVE.V
TSX
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.90% | 1.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.90% | 1.92% | |||
| Cost of Revenue | 0.53% | -5.56% | |||
| Gross Profit | 10.30% | 12.99% | |||
| SG&A Expenses | 3.49% | -1.56% | |||
| Depreciation & Amortization | -19.36% | -3.58% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.10% | -4.46% | |||
| Operating Income | 18.57% | 34.24% | |||
| Income Before Tax | 24.66% | 49.85% | |||
| Income Tax Expenses | 18.72% | 86.81% | |||
| Earnings from Continuing Operations | 27.20% | 38.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.20% | 38.18% | |||
| EBIT | 18.57% | 34.24% | |||
| EBITDA | 9.87% | 25.51% | |||
| EPS Basic | 25.78% | 37.63% | |||
| Normalized Basic EPS | 23.14% | 49.67% | |||
| EPS Diluted | 10.94% | 37.63% | |||
| Normalized Diluted EPS | 23.56% | 49.01% | |||
| Average Basic Shares Outstanding | 0.96% | 0.60% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||